Zimmer Biomet (ZBH)
(Delayed Data from NYSE)
$111.29 USD
+0.65 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$111.29 USD
+0.65 (0.59%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $111.30 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth C Momentum B VGM
Zacks News
Zimmer Biomet is a leading musculoskeletal healthcare company that designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants; and related surgical products. With operations in over 25 countries, Zimmer markets products in more than 100 countries. In 2015, Zimmer Holdings, Inc. (the legacy company) acquired Biomet, Inc. to form a new consolidated company.
Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.
Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 3.77% and 0.64%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Zimmer Biomet (ZBH) Might Surprise This Earnings Season
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Stay Ahead of the Game With Zimmer (ZBH) Q3 Earnings: Wall Street's Insights on Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.
Zimmer Biomet (ZBH) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Zimmer (ZBH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Zimmer Biomet (ZBH) Beat Estimates This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) third-quarter results are likely to reflect continued segmental strength.
ZBH or ABT: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ZBH vs. ABT: Which Stock Is the Better Value Option?
5 Large-Cap Stocks to Buy on the Dip for Q4 2023
by Nalak Das
We have narrowed our search to five large-cap (market capital > $10 billion) stocks with attractive valuations. These stocks are: TWLO, KDP, ULTA, ALGN, ZBH.
5 Medical Product Stocks to Buy Amid Industry Recovery
by Indrajit Bandyopadhyay
Despite the ongoing macro headwinds, recovering demand for medical procedures and cost-cutting initiatives should support the Zacks Medical-Products industry. SYK, BSX, ZBH, PODD and HAE are well-poised to gain from the favorable factors.
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) on business recovery and expansion in emerging markets.
Zimmer Biomet (ZBH) Gains From ROSA Sales Growth Amid FX Woes
by Zacks Equity Research
Zimmer Biomet (ZBH) plans to work on the overall shift of the company's legacy knee systems to a fully rounded-out Persona portfolio.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zimmer Biomet (ZBH) Business Recovery Continues Despite FX Woe
by Zacks Equity Research
Zimmer Biomet (ZBH) is benefiting from increased provider capacity, resulting in backlog pull-through in the recent quarters.
Here's Why You Should Retain Zimmer Biomet (ZBH) for Now
by Zacks Equity Research
Investors are optimistic about Zimmer Biomet (ZBH) due to innovative new product launches and solid execution.
National Vision (EYE) Gains From Store Openings Amid Cost Woes
by Zacks Equity Research
National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.
Here's Why You Should Buy SmileDirectClub (SDC) Stock Now
by Zacks Equity Research
Investors are likely to benefit from the SmileDirectClub (SDC) stock, backed by strategic alliances and targeted long-term growth.
Zimmer Biomet (ZBH) Q2 Earnings Match Estimates, View Raised
by Zacks Equity Research
Barring S.E.T., Zimmer Biomet (ZBH) records strong growth across each of its business segments in the second quarter.
Zimmer (ZBH) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zimmer Biomet (ZBH) Q2 Earnings Meet Estimates
by Zacks Equity Research
Zimmer (ZBH) delivered earnings and revenue surprises of 0% and 2.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Zacks Industry Outlook Highlights Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics
by Zacks Equity Research
Abbott Laboratories, Stryker, Zimmer Biomet and Haemonetics are part of the Zacks Industry Outlook article.
Globus Medical (GMED) Gains on Innovation, Strategic Deal
by Zacks Equity Research
Globus Medical's (GMED) Enabling technology sales improvement is driven by strong performance of its robotic and imaging system.
Is a Surprise Coming for Zimmer Biomet (ZBH) This Earnings Season?
by Zacks Equity Research
Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.